Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04605991 · ClinicalTrials.gov registry record · Phase 3

A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)

A Phase 3 study of Type 2 Diabetes, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 3
Development phase
187
Enrollment target
20
Study locations

NCT04605991 is a Phase 3 study of Type 2 Diabetes that has completed, run by Eli Lilly and Company. The registered enrollment target is 187 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04605991, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 3
Development phase
187 participants
Enrollment target
20
Study locations

Study Summary

This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine. Participants will use continuous glucose monitoring (CGM) (Freestyle Libre 14-day system) during the study.

Conditions Studied

Type 2 Diabetes

Interventions

  • DRUG Insulin Glargine
  • DRUG LY900014

Study Locations (20)

California

  • John Muir Physician Network Clinical Research Center - Concord
  • AMCR Institute - Escondido
  • Valley Endocrine, Fresno - Fresno
  • University Clinical Investigators, Inc. - Tustin
  • Coastal Metabolic Research Centre - Ventura

Florida

  • Encore Medical Research - Hollywood
  • Sun Coast Clinical Research, Inc - New Port Richey
  • Metabolic Research Institute, Inc. - West Palm Beach

Georgia

  • Atlanta Diabetes Associates - Atlanta
  • East Coast Institute for Research at The Jones Center - Macon

Maryland

  • Maryland Cardiovascular Specialists - Baltimore
  • Endocrine and Metabolic Consultants - Rockville

Nevada

  • Palm Research Center Tenaya - Las Vegas
  • Palm Research Center Tenaya - Las Vegas

New York

  • Research NYC, Inc - New York
  • Suny Health Science Center at Syracuse - Syracuse

Connecticut

  • CMR of Greater New Haven - Hamden

Idaho

  • Rocky Mountain Clinical Research - Idaho Falls

Trial Details

FieldValue
Enrollment Target 187 participants
Start Date 2020-11-04
Est. Completion 2022-02-04
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04605991

The ClinicalTrials.gov registry entry for NCT04605991 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (83% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Insulin Glargine is the first listed.

NCT04605991 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT04605991 about?

NCT04605991 is a clinical study titled "A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)". This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine. Participants will use continuous glucose monitoring (CGM) (Freestyle Libre 14-day system) during the study.

What is the current status of trial NCT04605991?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 187 participants. The study started on 2020-11-04. Estimated completion is 2022-02-04.

What conditions does trial NCT04605991 study?

This clinical trial studies the following conditions: Type 2 Diabetes.

What interventions are being tested in trial NCT04605991?

The interventions under investigation include: Insulin Glargine (DRUG), LY900014 (DRUG).

Who is sponsoring clinical trial NCT04605991?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04605991 being conducted?

This trial has 20 study locations across California, Connecticut, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.